News

September marks Pulmonary Fibrosis Awareness Month, presented by the Pulmonary Fibrosis Foundation (PFF) to spread the word about pulmonary fibrosis (PF), a progressive, incurable lung disease with different causes affecting more than 200,000 people in the U.S. While more than 50,000 new cases are diagnosed annually, awareness of PF symptoms, which include shortness of breath, fatigue and a dry, hacking cough, remains very low for a vast majority (86%) of Americans, according to the PFF.

The Pulmonary Fibrosis Foundation is committed to its mission to drive research and act as the trusted resource for individuals afflicted with pulmonary fibrosis. We exist to serve people of every race and background, and we know that the suffering resulting from PF is often accompanied by other painful hardships borne by patients and their loved ones.

The Pulmonary Fibrosis Foundation (PFF) announced the appointment of three highly respected pulmonologists as senior members of its medical team. The new team members are: Dr. Amy Hajari Case of Piedmont Healthcare (Atlanta); Dr. Sonye Danoff of the Johns Hopkins University School of Medicine (Baltimore); and Dr. Joyce Lee of the University of Colorado Anschutz Medical Campus (Aurora). They will bring a combined 40-plus years of expertise in treating individuals with interstitial lung disease (ILD).

Pulmonary fibrosis patients are at high-risk of complications related to COVID-19 and need protections that reduce their chance for exposure to the virus. At the same time, many pulmonary fibrosis patients rely on pulmonary rehabilitation (PR) services. PR has been shown to improve many PF patients’ exercise capacity and health-related quality of life. Because there are limited treatment options for PF, pulmonary rehabilitation is all the more essential for helping to maintain PF patients’ health.

CMS guidelines for supplemental oxygen adjusted to protect patients during COVID-19 crisis

To limit or prevent the spread of COVID-19, several recommendations have been suggested by the Centers for Disease Control (CDC). Read our FAQ for pulmonary fibrosis patients.